HCDS -> RespiFit: development of a device for detecting tuberculosis mycobacterium

development of a device for detecting tuberculosis mycobacterium

The Hellenic Chest Diseases Society (H.C.D.S), supporting research in pulmonology, is proceeding to the initial funding of the company RespiFit LTD for the development of a prototype device for the detection of tuberculosis mycobacterium dispersed in air. About one quarter of the world population is thought to have latent infection with TB and more than one million people die each year.

RespiFit is a Digital Health SME providing personalized respiratory disease management and focusing on the intelligent monitoring of chronic respiratory diseases (e.g., asthma, COPD) as well as bio-safety against infectious disease agents.

 

We wish to RespiFit Good luck and the best results!

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

share on :

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on email

become a member of HCDS

and gain access to important announcements, upcoming events, educational courses and more.